• Blau posted 1H26 net revenue of BRL 922 million, up 10%.
• 2Q26 net revenue rose 5% to BRL 487 million; 1Q26 net revenue climbed 17% to BRL 435 million.
• 1H26 gross margin improved 240 bps to 43.2%; 2Q26 gross margin rose 330 bps to 43.6%.
• 1H26 recurring EBITDA margin edged up 40 bps to 24.9%; 2Q26 recurring EBITDA margin was 25.9%.
• 1H26 recurring net income fell 15% to BRL 107 million; excluding FX variation, it rose 18% to BRL 134 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.